genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2019
Immatics Biotechnologies
Cancer
Celgene, Immatics Launch Up-to-$1.5B+ Cancer T-Cell Collaboration
Cancer
Genmab, Immatics Launch Up-to-$2.8B+ Cancer Immunotherapy Partnership
Drug Discovery
Amgen, Immatics Launch Up-to-$1B+ Cancer Immunotherapy Alliance
Cancer
Immatics Raises Nearly €54M to Take Lead Therapeutic Cancer Vaccine into Phase III
Cancer
Scancell and Immatics to Explore Combination of Vaccine Technologies for Colorectal Cancer
Cancer
Cancer Research UK to Conduct Phase I Study with Immatics Glioblastoma Vaccine
Scroll Up
Scroll Up
